Literature DB >> 20589657

Matched unrelated umbilical cord blood transplantation for a patient with chemotherapy resistant Wilms tumor.

Kenneth G Lucas1, Terry Shapiro, Andrew Freiberg, Elizabeth Frauenhoffer.   

Abstract

We report a patient with chemotherapy refractory Wilms tumor who underwent an unrelated donor cord blood transplant for chemotherapy refractory disease. The preparative regimen consisted of busulfan, melphalan, and anti-thymocyte globulin, and was well tolerated. This patient did not experience significant toxicity related to the chemotherapy regimen and did not develop any graft versus host disease from his HLA (A, B, DR) 6/6 matched cord blood transplant. Follow-up CT scans 2 years post-transplant have shown no evidence of disease progression, with only a few pulmonary nodules remaining, which are unchanged in size from his pre-transplant CT scan. It is possible that high-dose chemotherapy and stem cell transplantation can be curative in patients with tumors that are non-responsive to conventional chemotherapy. Copyright 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20589657     DOI: 10.1002/pbc.22635

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  2 in total

1.  High dose therapy for recurrent Wilms' tumor.

Authors:  Thomas W McLean
Journal:  Transl Pediatr       Date:  2014-01

Review 2.  Natural Killer Cells: Development, Maturation, and Clinical Utilization.

Authors:  Alex M Abel; Chao Yang; Monica S Thakar; Subramaniam Malarkannan
Journal:  Front Immunol       Date:  2018-08-13       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.